THE NEW GATEKEEPERS

News
Article

Changing market conditions are catapulting pharmacists into the pivotal role of patrolling a third class of drugs.

Recent Videos
Related Content
FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain

FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain

Lauren Massaro
October 29th 2024
Article

The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

Lauren Biscaldi, MS, Managing Editor
October 23rd 2024
Article

Abrysvo is the only RSV vaccine approved for use in this age group.

Gepotidacin NDA Under Priority Review by FDA for Uncomplicated UTI

Gepotidacin NDA Under Priority Review by FDA for Uncomplicated UTI

Lauren Biscaldi, MS, Managing Editor
October 16th 2024
Article

Gepotidacin is a first-in-class oral antibiotic with a novel mechanism of action.

FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease

FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease

Kevin W. Chamberlin, PharmD, FASCP;Molly Csere, PharmD
October 15th 2024
Article

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

FDA Approves Ceftobiprole Medocaril Sodium for 3 Indications

FDA Approves Ceftobiprole Medocaril Sodium for 3 Indications

Jenny Zhao, PharmD;Kevin W. Chamberlin, PharmD, FASCP
October 14th 2024
Article

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

© 2024 MJH Life Sciences

All rights reserved.